Overview
- The first book to systematically cover the issue of how to integrate network biology, systems biology and polypharmacology
- The only book dealing with the proposal of a paradigm shift in drug discovery focused on the network pharmacology
- Brings together a group of top scholars on the much-debated issue of Systems-oriented drug design
Part of the book series: Human Perspectives in Health Sciences and Technology (HPHST, volume 2)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (19 chapters)
-
Front Matter
Keywords
- Efficiency of multi-target drugs
- Failing drug discovery
- Failure of current medical treatments
- Medical treatments for chronic diseases
- Multi-target drugs
- Network-based pharmacology
- Polypharmacology
- Precision medicine
- Systems-oriented drug design
- Synthesis between oriental and western medicine
- Systems-oriented drug design
- The tumor microenvironment
- The era of failing drug discovery
- Systems Biology
About this book
This volume – for pharmacologists, systems biologists, philosophers and historians of medicine – points to investigate new avenues in pharmacology research, by providing a full assessment of the premises underlying a radical shift in the pharmacology paradigm. The pharmaceutical industry is currently facing unparalleled challenges in developing innovative drugs. While drug-developing scientists in the 1990s mostly welcomed the transformation into a target-based approach, two decades of experience shows that this model is failing to boost both drug discovery and efficiency. Selected targets were often not druggable and with poor disease linkage, leading to either high toxicity or poor efficacy. Therefore, a profound rethinking of the current paradigm is needed. Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggest that exquisitely selective compounds, compared with multitarget drugs, may exhibit lower than desired clinical efficacy. This appreciation of the role of polypharmacology has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity. Integrating network biology and polypharmacology holds the promise of expanding the current opportunity space for druggable targets.
Editors and Affiliations
About the editor
Mariano Bizzarri PhD, M.D., is Associate Professor of Clinical Pathology in the Department of Experimental Medicine at University Sapienza, Rome (Italy). He was appointed as member of the Italian Space Agency (ASI) Scientific Committee in 2005 and he was elected President of that Committee in 2011-2014. He is a co-founder of the Italian Society for Space Biomedicine and Biochemistry (2006). Head of the Interdepartmental Systems Biology Center and member of the Space Research Interdepartmental Center of the University La Sapienza (CRAS). He is the Editor in Chief of the international journal ORGANISMS. He has authored hundreds of scientific and philosophical essays, as well as of dozen of scientific books, among which Systems Biology (Springer protocols, 2017).
Bibliographic Information
Book Title: Approaching Complex Diseases
Book Subtitle: Network-Based Pharmacology and Systems Approach in Bio-Medicine
Editors: Mariano Bizzarri
Series Title: Human Perspectives in Health Sciences and Technology
DOI: https://doi.org/10.1007/978-3-030-32857-3
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer Nature Switzerland AG 2020
Hardcover ISBN: 978-3-030-32856-6Published: 18 April 2020
Softcover ISBN: 978-3-030-32859-7Published: 18 April 2021
eBook ISBN: 978-3-030-32857-3Published: 17 April 2020
Series ISSN: 2661-8915
Series E-ISSN: 2661-8923
Edition Number: 1
Number of Pages: XVI, 483
Number of Illustrations: 8 b/w illustrations, 41 illustrations in colour
Topics: Pharmacology/Toxicology, Systems Biology, Oncology, Philosophy of Medicine